|
Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB Clinical research trials and Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB. Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB  Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB
Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB
For Condition: Cardiac Surgery,Coronary Artery Bypass Surgery
Status: No longer recruiting
Sponsor(s): The Medicines Company ,
Synopsis: The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: - Provide written informed consent before initiation of any study related procedures. - Be at least 18 years of age. - Be accepted for elective off-pump coronary artery bypass graft (CABG) surgery without concomitant cardiac surgical procedures. - < 4 planned Coronary Artery Bypass Grafts Exclusion: - Any prior Cardio-Thoracic Surgical procedures requiring median sternotomy - Confirmed pregnancy – baseline urine or serum pregnancy test (if woman of childbearing potential). - Cerebrovascular accident within 6 months before randomization, or any cerebrovascular accident with residual neurological deficit. - Intracranial neoplasm, arteriovenous malformation, or aneurysm. - Dependency on renal dialysis or creatinine clearance <30mL/min. - Ongoing treatment with warfarin (or other oral anticoagulants) at the time of randomization. Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is <1.3 times control in the absence of heparin therapy. - Known allergy to Angiomax or hirudin derived drugs, or known sensitivity to any component of these products. - Patients receiving clopidogrel within the previous 5 days of randomization. - Patients receiving a glyoprotein IIb/IIIa inhibitor within 48 hours if abciximab (ReoPro) or within 24 hours if eptifibatide (Integrilin) and tirofiban (Aggrastat) of randomization - Patients receiving lepirudin or argatroban within the previous 24 hours of randomization. - Patients receiving low molecular weight heparin (LMWH) or thrombolytics within the previous 12 hours or unfractionated heparin within 30 minutes of randomization. - Patients with active or prior history of heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS)*. - Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization. - Refusal to undergo blood transfusion should it become necessary. - Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial or inability to comply with study requirements.
Total Enrollment: 150
Location and Contact Information:
Overall Study Official:
AndrewSternlicht, Study Director, The Medicines Company
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
United States
Additional Information:
Study ID Numbers: TMC-BIV-02-07; EVOLUTION
Study Start Date: September 2003
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073593
Other Coronary Artery Bypass Surgery Studies:
1. Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
2. Angiomax in Patients with HIT/HITTS Type II Undergoing CPB
3. Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB
Related Studies:
Other Coronary Artery Bypass Surgery Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB
|
|
|
|
|
|
|
|
